Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L26 pseudogene 3 (RPL26P3) is a processed pseudogene found in the human genome. Pseudogenes are DNA sequences similar to functional genes but generally lack protein-coding ability due to accumulated mutations. RPL26P3 is derived from the gene encoding ribosomal protein L26, a structural component of the large 60S ribosomal subunit and part of the universal ribosomal protein family. While ribosomal protein L26 (RPL26) plays an essential role in protein synthesis, its pseudogenes (such as RPL26P3) are non-functional, do not encode proteins, and have no known biological activities or therapeutic relevance[1][2][4]. Summary of classification and relevance: RPL26P3 is a non-coding, non-functional pseudogene related to ribosomal protein L26, with no known biological function, disease association, or role as a drug target. It should not be considered a therapeutic target. There is nothing incorrect about its naming or description, but its inclusion in pharmacological or therapeutic target lists would be inappropriate as it does not meet functional criteria for such classification[1][2].
None (as there are no drugs targeting this pseudogene[1][2])
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L26 pseudogene 3 (RPL26P3).